The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.
SwanBio Therapeutics, a US-based gene therapy developer focused on adeno-associated virus-based treatments for inherited neurological conditions, has closed a $56m series B round co-led by Syncona and Mass General Brigham Ventures, the investment arm of health system Mass General Brigham. The Harvard University spinout has bow raised $133m altogether, after Syncona had already contributed to a $77m series A round in 2020.
Nikola Labs, a US-based provider of sensor-based reliability technology to remotely monitor manufacturing infrastructure, has raised $20m…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
